Prestige Consumer Healthcare Inc (PBH)
69.85
-1.37
(-1.92%)
USD |
NYSE |
Apr 24, 15:00
Prestige Consumer Healthcare Enterprise Value: 4.672B for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 4.672B |
| April 22, 2024 | 4.601B |
| April 19, 2024 | 4.595B |
| April 18, 2024 | 4.529B |
| April 17, 2024 | 4.513B |
| April 16, 2024 | 4.515B |
| April 15, 2024 | 4.519B |
| April 12, 2024 | 4.523B |
| April 11, 2024 | 4.571B |
| April 10, 2024 | 4.558B |
| April 09, 2024 | 4.570B |
| April 08, 2024 | 4.543B |
| April 05, 2024 | 4.569B |
| April 04, 2024 | 4.600B |
| April 03, 2024 | 4.583B |
| April 02, 2024 | 4.609B |
| April 01, 2024 | 4.695B |
| March 28, 2024 | 4.738B |
| March 27, 2024 | 4.742B |
| March 26, 2024 | 4.710B |
| March 25, 2024 | 4.690B |
| March 22, 2024 | 4.773B |
| March 21, 2024 | 4.804B |
| March 20, 2024 | 4.779B |
| March 19, 2024 | 4.788B |
| Date | Value |
|---|---|
| March 18, 2024 | 4.791B |
| March 15, 2024 | 4.843B |
| March 14, 2024 | 4.811B |
| March 13, 2024 | 4.863B |
| March 12, 2024 | 4.817B |
| March 11, 2024 | 4.839B |
| March 08, 2024 | 4.795B |
| March 07, 2024 | 4.741B |
| March 06, 2024 | 4.681B |
| March 05, 2024 | 4.673B |
| March 04, 2024 | 4.709B |
| March 01, 2024 | 4.618B |
| February 29, 2024 | 4.590B |
| February 28, 2024 | 4.590B |
| February 27, 2024 | 4.604B |
| February 26, 2024 | 4.610B |
| February 23, 2024 | 4.597B |
| February 22, 2024 | 4.581B |
| February 21, 2024 | 4.576B |
| February 20, 2024 | 4.550B |
| February 16, 2024 | 4.568B |
| February 15, 2024 | 4.551B |
| February 14, 2024 | 4.497B |
| February 13, 2024 | 4.440B |
| February 12, 2024 | 4.509B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.156B
Minimum
Mar 23 2020
4.863B
Maximum
Mar 13 2024
3.966B
Average
4.067B
Median
Jan 16 2024
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.275M |
| Palatin Technologies Inc | 18.75M |
| iBio Inc | 16.49M |
| Theriva Biologics Inc | -13.75M |
| Oragenics Inc | 3.306M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 53.05M |
| Revenue (Quarterly) | 282.74M |
| Total Expenses (Quarterly) | 195.91M |
| EPS Diluted (Quarterly) | 1.06 |
| Gross Profit Margin (Quarterly) | 55.86% |
| Profit Margin (Quarterly) | 18.76% |
| Earnings Yield | -2.35% |
| Operating Earnings Yield | 10.00% |
| Normalized Earnings Yield | -2.348 |